Acute-onset autoimmune type 1 diabetes presenting with diabetic ketoacidosis in an obese adult.

Proc (Bayl Univ Med Cent)Apr 20, 2026 (epub)
Case ReportEndocrinologyOpen access

David Kweku Aseda Donkor, Venkata Siva Dilisha Chandanala, Toluwalase Akinfisoye et al.

✦ AI-curated · Sources linked

Case in brief

A 51-year-old obese man presented with severe diabetic ketoacidosis, characterized by hyperglycemia of 1297 mg/dL and metabolic acidosis. Laboratory tests revealed strong positivity for glutamic acid decarboxylase antibodies and very low C-peptide levels, indicating significant insulin deficiency. The patient was treated with standard DKA management and subsequently discharged on insulin therapy, highlighting the atypical presentation of autoimmune type 1 diabetes in adults.

Diagnostic / clinical pearl

In adults with new-onset diabetes and significant insulin deficiency, measuring islet autoantibodies and C-peptide is crucial to prevent misclassification and ensure appropriate insulin therapy.

Why it matters

This case underscores that obesity does not rule out autoimmune type 1 diabetes, emphasizing the need for comprehensive diagnostic evaluation in atypical presentations.

Source

Published in Proc (Bayl Univ Med Cent). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.